Wednesday, December 21, 2011
Tuesday, December 13, 2011
Buspar for Autism? (buspirone hydrochloride,Vanspar)
Autism Therapy: Buspar (buspirone hydrochloride) | Healing Thresholds
Autism Therapy: Buspar (buspirone hydrochloride)
definition of Buspar (buspirone hydrochloride): Buspar® is indicated for the management of anxiety disorders or for short-term relief of more severe symptoms of anxiety. Buspirone may be prescribed off-label for people with autism to help reduce anxiety and aggression and to help improve behaviors. Buspirone has helped improve behaviors in some people with autism. This medication is currently being tested in children and adults with autism.
Friday, December 9, 2011
Response Interruption/Redirection (RIR)
Response Interruption/Redirection | autismpdc.fpg.unc.edu
OVERVIEW: Response interruption/redirection (RIR) is an evidence-based practice used to decrease interfering behaviors, predominantly those that are repetitive, stereotypical, and/or self-injurious. RIR often is implemented after a functional behavior assessment (FBA) has been conducted to identify the function of the interfering behavior. RIR is particularly useful with persistent interfering behaviors that occur in the absence of other people, in a number of different settings, and during a variety of tasks. These behaviors often are not maintained by attention or escape. Instead, they are more likely maintained by sensory reinforcement and are often resistant to intervention attempts. RIR is particularly effective with sensory-maintained behaviors because teachers/practitioners interrupt learners from engaging in interfering behaviors and redirect them to more appropriate, alternative behaviors.
Thursday, December 8, 2011
Gaming treatment for autism
Gaming treatment for autism used in Issaquah - KAYU
One in every 110 kids in the United States have autism, but the Lakeside Center for Autism in Issaquah is turning technology into treatment.
"It`s always a barrier for our kids with autism to connect socially and with peers especially," said Lakeside counselor Peiera Miller.
That's where the Kinect comes in. The gaming system is helping to teach basic skills most of us take for granted.
When Landon Kacatin arrived at Lakeside three years ago, he wasn't talking. "He's OK with adults, but with children that's very difficult for him; he would avoid it all the time," said his mother, Laconia Kacatin.
After just a year of playing games on the Kinect, Landon isn't just talking to other kids, he's rooting for them.
CM-AT Trial Targeting Core Symptoms of Autism
Autism Jabberwocky: First Drug Targeting Core Symptoms of Autism Nears?
Curemark LLC Reports Positive Phase III Results of CM-AT In Children With Autism
Wednesday, December 7th - 2011
RYE, New York, Dec. 7, 2011 – Curemark LLC, a Rye, New York-based drug research and development company, today announced that its Phase III double blind randomized placebo controlled multicenter clinical trial of CM-AT for autism met its primary and secondary endpoints. The trial compared CM-AT to placebo in children with autism aged 3 – 8. Top line results demonstrate a statistically significant effect of CM-AT over placebo on both core and non-core symptoms of autism. Analysis of the full trial data is ongoing and the results will be presented at an upcoming medical meeting.
“We are extremely pleased with the results of our trial,” said Dr. Joan Fallon, CEO of Curemark. “We wish to thank all the children and their parents who participated in the study, and look forward to a full review of the data by the FDA.”
CM-AT has been granted Fast Track status by the Food and Drug Administration (FDA). The fast track programs of the Food and Drug Administration are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.
Wednesday, December 7, 2011
Acupuncture for Autism?
Abstract
Background. There has been lack of reviews of evidence on efficacy, methodology, and/or safety of acupuncture in autism spectrum disorders. This paper examines the emerging evidence of the effects of acupuncture in the treatment of autistic children. Method. A literature review was completed via Medline and three Chinese search engines. A total of 31 studies were evaluated for acupuncture methodology, study design, treatment effects, and tolerability. Results. The acupoints used, the duration of needling, the frequency of treatment, the choice of stimulation, and the course of the treatment were highly variable amongst the studies. Behavioral and/or developmental improvements were reported in all acupuncture treatment studies. All studies reported general tolerability. Weakness of experimental designs was discussed. Conclusions. Vigorously controlled double-blinded clinical trials are needed to evaluate the efficacy and safety of acupuncture in children with autism spectrum disorders.
ScienceDirect - Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease : Mast cell activation and autism
ScienceDirect - Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease : Mast cell activation and autism
Research Highlights
►Allergic problems are common in autistic individuals. ►Perinatal mast cell activation may contribute to brain inflammation. ►The peptide neurotensin is increased in serum of autistic individuals.
Ecstasy (MDMA) Autism Treatment?
Can Ecstasy Treat Autism? | Drugs | AlterNet
A team of scientists at a California non-profit organization just announced a pilot study to determine if Ecstasy might help fight the effects of autism. This isn’t the first time that MAPS, or the Multidisciplinary Association for Psychedelic Studies, has researched the psychiatric benefits of MDMA. A 2010 study of twenty Iraq veterans suffering from Post-Traumatic Stress Disorder found that a combination of Ecstasy and therapy resulted in an 80-percent success rate, high enough to convince the Food and Drug Administration to greenlight further studies of the drug.
Lexapro for Pervasive Developmental Disorders
An open-label trial of es... [J Am Acad Child Adolesc Psychiatry. 2005] - PubMed - NCBI
OBJECTIVE:
To assess the effect of escitalopram in the treatment of pervasive developmental disorders (PDDs).
METHOD:
This 10-week study had a forced titration, open-label design. Twenty-eight subjects (mean age 125.1 +/- 33.5 months) with a PDD received escitalopram at a dose that increased weekly to a maximum dose of 20 mg as tolerated. The Aberrant Behavior Checklist-Community Version (ABC-CV) and the Clinical Global Impression scale (CGI) were used to assess outcome.
Subscribe to:
Posts (Atom)
Add This ...
